Rebecca Dent

机构：Duke-NUS Medical School, National Cancer Centre Singapore · ORCID：0000-0001-6421-7602

发表论文 321 篇 · 总被引 23538 次 · h-index 58

代表论文

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial (2026 · Annals of Oncology · 被引 12)
Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC (2025 · Clinical Cancer Research · 被引 11)
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06 (2025 · ESMO Open · 被引 7)
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (2025 · Clinical Cancer Research · 被引 5)
Evaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting (2025 · Annals of the Academy of Medicine Singapore · 被引 4)
Advancing breast cancer research through real-world data from the Singapore Joint Breast Cancer Registry (2025 · ESMO Real World Data and Digital Oncology · 被引 4)